Electrophysiologic effects, efficacy and tolerance of class Ic antiarrhythmic agents in Wolff-Parkinson-White syndrome.

[1]  A. Manolis,et al.  Sensitivity and specificity of programmed atrial stimulation for induction of supraventricular tachycardias , 1988, Clinical cardiology.

[2]  N. Fineberg,et al.  Encainide for treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome. , 1986, The American journal of cardiology.

[3]  E. Shinebourne,et al.  Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff-Parkinson-White syndrome. , 1986, The American journal of cardiology.

[4]  M. Shenasa,et al.  Evaluation of flecainide acetate in rapid atrial fibrillation complicating wolff‐parkinson‐white syndrome , 1985, Clinical cardiology.

[5]  K. Kuck,et al.  Electrophysiologic and clinical effects of intravenous and oral encainide in accessory atrioventricular pathway. , 1984, The American journal of cardiology.

[6]  E. Prystowsky,et al.  Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome. , 1984, Circulation.

[7]  A. Camm,et al.  Cardiac electrophysiologic effects of flecainide acetate for paroxysmal reentrant junctional tachycardias. , 1983, The American journal of cardiology.

[8]  W. Dassen,et al.  Effect of drugs in the Wolff-Parkinson-White syndrome. Importance of initial length of effective refractory period of the accessory pathway. , 1980, The American journal of cardiology.

[9]  T. D. Sellers,et al.  Ventricular fibrillation in the Wolff-Parkinson-White syndrome. , 1979, The New England journal of medicine.